In this segment, expert faculty discuss key considerations with immune checkpoint inhibitor therapy, including multidisciplinary care, patient monitoring, use of immunotherapy in the presence of Child-Pugh B cirrhosis, risk of HBV/HCV reactivation, and adverse event management.
Lipika Goyal, MD
Amit G. Singal, MD, MS
Released: November 24, 2020Expiration: No longer available for credit
This program is divided into several short segments which you can step through using the Video Chapters menu.